Thiazolidinediones-PPAR-γ Agonists; for the treatment of Type II Diabetes Mellitus.

Current treatment for diabetes mellitus cannot treat Insulin insensitivity, resistance, and destruction of the beta cells of the pancreas. Thiazolidinediones are the class of the drugs that binds to the PPAR-γ receptors and make proper utilization of secreted insulin by reducing insensitivity. It also reduces the lipid crowd in the liver. Increases the storage capacity in the adipose tissues for the triglycerides and the free fatty acid. The TZDs are reported with some side effects like CHF due to water retention, bone fracture, gain of the body weight, and bladder cancers are discussed in the review. [ABSTRACT FROM AUTHOR]